Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EraGen Biosciences

This article was originally published in Start Up

Executive Summary

EraGen is developing hardware and software tools for genomics analysis including Master Catalog, a web-based tool that combines genomic database organization and search capabilities with evolutionary biological information, and AEGIS, a technology for direct DNA detection without the need for target amplification.

You may also be interested in...



Post-Genomics

With so much genomics data and putative drug targets to sift through, drug developers cannot risk making research resource allocation decisions before correlating gene and protein function with a disease process. The need has spawned a new generation of post-genomics companies focused on developing tools for validating drug targets, including smart screening methodologies and cell-based assays, and on ways to better organize and characterize genomics and proteomics data.

Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Science Matters: Glimmers Of Hope For Treating ALS

Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090199

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel